JPWO2023120551A1 - - Google Patents
Info
- Publication number
- JPWO2023120551A1 JPWO2023120551A1 JP2023569475A JP2023569475A JPWO2023120551A1 JP WO2023120551 A1 JPWO2023120551 A1 JP WO2023120551A1 JP 2023569475 A JP2023569475 A JP 2023569475A JP 2023569475 A JP2023569475 A JP 2023569475A JP WO2023120551 A1 JPWO2023120551 A1 JP WO2023120551A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021206572 | 2021-12-21 | ||
| PCT/JP2022/047004 WO2023120551A1 (ja) | 2021-12-21 | 2022-12-21 | 自閉スペクトラム症治療のためのオピオイドの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023120551A1 true JPWO2023120551A1 (https=) | 2023-06-29 |
| JPWO2023120551A5 JPWO2023120551A5 (https=) | 2025-12-16 |
Family
ID=86902678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569475A Pending JPWO2023120551A1 (https=) | 2021-12-21 | 2022-12-21 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250073226A1 (https=) |
| EP (1) | EP4454649A4 (https=) |
| JP (1) | JPWO2023120551A1 (https=) |
| CN (1) | CN118434419A (https=) |
| TW (1) | TW202329963A (https=) |
| WO (1) | WO2023120551A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5931884B2 (ja) * | 2010-10-07 | 2016-06-08 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症の生菌療法 |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| EP2859890A3 (en) * | 2011-10-31 | 2015-08-05 | The Johns Hopkins University | Methods and compositions for treatment of autism |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| US11491144B2 (en) * | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| US11160843B2 (en) | 2018-04-30 | 2021-11-02 | Yale University | Oxytocin and opioid antagonists for treatment of social dysfunction disorder |
-
2022
- 2022-12-21 JP JP2023569475A patent/JPWO2023120551A1/ja active Pending
- 2022-12-21 US US18/722,305 patent/US20250073226A1/en active Pending
- 2022-12-21 TW TW111149205A patent/TW202329963A/zh unknown
- 2022-12-21 EP EP22911253.7A patent/EP4454649A4/en active Pending
- 2022-12-21 CN CN202280084611.1A patent/CN118434419A/zh active Pending
- 2022-12-21 WO PCT/JP2022/047004 patent/WO2023120551A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW202329963A (zh) | 2023-08-01 |
| EP4454649A4 (en) | 2025-11-26 |
| EP4454649A1 (en) | 2024-10-30 |
| WO2023120551A1 (ja) | 2023-06-29 |
| US20250073226A1 (en) | 2025-03-06 |
| CN118434419A (zh) | 2024-08-02 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240620 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A801 Effective date: 20240718 |
|
| A80 | Written request to apply exceptions to lack of novelty of invention |
Free format text: JAPANESE INTERMEDIATE CODE: A80 Effective date: 20240718 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251205 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251205 |